Learn · Weight
Is Compounded Semaglutide FDA Approved?
No — compounded semaglutide is not FDA approved.[1] Here's what that actually means, why it existed, and where the rules stand in 2026, in plain English.
General information, not medical advice · A medical provider licensed in your state makes every medical decision
The straight answer, up front
What's true as of July 2026
Compounded semaglutide is not FDA-approved. Compounded medications are not FDA-approved. They are prepared in FDA-regulated facilities. Per the FDA, "the agency does not review compounded drugs for safety, effectiveness or quality before they are marketed."[1]
On February 21, 2025, the FDA announced it had determined the shortage of semaglutide injection products is resolved — which narrowed the legal room to compound copies.[2]
Wind-down windows ended in 2025: April 22, 2025 for state-licensed pharmacies (503A); May 22, 2025 for outsourcing facilities (503B).[2]
The FDA's compounder update states that tirzepatide and semaglutide "do not currently appear on the 503B bulks list or on FDA's drug shortage list."[2]
What "not FDA approved" actually means
When a medication is "FDA approved," it has gone through the agency's premarket review — a rigorous evaluation for safety, effectiveness, and quality before it can be sold. Compounded drugs do not go through that process — per the FDA, "the agency does not review compounded drugs for safety, effectiveness or quality before they are marketed."[1] That doesn't automatically make them illegal or unsafe, but it does mean no federal agency has reviewed that specific compounded preparation the way it reviews an approved product. You are trusting the facility and the prescriber, not an FDA approval.
Why compounded semaglutide became so common
Semaglutide injection products had been in shortage since 2022 due to increased demand.[2] During a recognized shortage, federal law allows licensed pharmacies (under section 503A) and registered outsourcing facilities (under section 503B) to compound versions of a medication so patients can still be treated.[2] That is why compounded semaglutide was widely available and affordable for a stretch — it was a shortage response, not a permanent FDA stamp of approval.
What changed in 2025
On February 21, 2025, the FDA announced it had determined the shortage of semaglutide injection products was resolved.[2] Once a shortage ends, the legal room to compound copies narrows sharply. The FDA set wind-down windows for compounding tied to the shortage: for state-licensed pharmacies and physicians (503A), enforcement discretion ended April 22, 2025; for outsourcing facilities (503B), May 22, 2025.[2] The FDA's compounder update now states that tirzepatide and semaglutide "do not currently appear on the 503B bulks list or on FDA's drug shortage list."[2]
Where it stands in 2026
The picture is still moving, which is exactly why a "last reviewed" date matters on a page like this. On April 30, 2026, the FDA proposed to exclude semaglutide (along with tirzepatide and liraglutide) from the 503B bulks list, "finding no clinical need for outsourcing facilities to compound these drugs from bulk substances."[3]
The agency invited public comments by June 29, 2026, then extended the comment period to July 30, 2026; either electronic or written comments must be submitted by July 30, 2026, and the FDA will consider them before making a final determination.[4]
In related litigation over compounded semaglutide, the district court denied the plaintiffs' preliminary injunction motion in Outsourcing Facilities Association v. FDA on April 24, 2025.[2] Bottom line: the legal footing for routine compounded semaglutide is far narrower than it was in 2024, and it is still being decided.
"Not FDA-approved" is not the same as "illegal" — and it is not the same as "safe." It means the specific preparation in the vial was never reviewed by the FDA at all.[1] Anyone who blurs that line is selling, not informing.
So what should you actually do?
If you're weighing GLP-1 weight management, the honest path is to talk with a medical provider licensed to practice in your state about your options and the current status of any medication you're considering — including FDA-approved brand-name products. The right choice depends on your health history, and only a medical provider can advise you on your health. Ladies First provides marketing services; medical decisions are made by your medical provider. A page can give you the lay of the land; it can't prescribe.
Related reading: Are compounded semaglutides safe? · Compounded tirzepatide · Are semaglutides safe?
How Ladies First fits in
Ladies First provides marketing and advertising services — we are not a medical provider. Medical services are provided by our medical provider partner, and all medical decisions are made by a medical provider licensed in your state. We don't compound, manufacture, or dispense medication — and we won't tell you a medication is something it isn't.
Questions women actually ask
Is compounded semaglutide interchangeable with Ozempic® or Wegovy®?
No — it is not the same drug. Ozempic® and Wegovy® (Novo Nordisk) are FDA-approved products that went through premarket review.[5]
Compounded semaglutide is not FDA-approved,[1] and the FDA lists it as a telehealth red flag when a company claims its product "is the same as an FDA-approved drug."[1] The FDA has also noted that some semaglutide products sold by compounders may be salt forms — semaglutide sodium and semaglutide acetate — which it says "are different active ingredients than are used in the approved drugs."[1]
Is compounded semaglutide illegal?
Compounding is legal under specific conditions in sections 503A and 503B of federal law.[2] After the 2025 shortage resolution, the conditions that allowed broad compounding of semaglutide narrowed.[2]
In April 2026 the FDA also proposed to exclude semaglutide from the 503B bulks list, finding no clinical need for outsourcing facilities to compound these drugs from bulk substances.[3]
Legality depends on those conditions being met — it is not a blanket yes or no.
Is it safe?
"Not FDA-approved" doesn't tell you a preparation is safe or unsafe on its own — it means the specific preparation was never reviewed by the FDA at all, so there's no FDA approval to rely on.[1] Safety depends on your health profile, the compounding facility, and the oversight of your prescriber and pharmacy, and individual results vary. Discuss it with a medical provider licensed to practice in your state.
Why was it so much cheaper?
Compounded versions were priced differently and were available during the shortage. Price is not a measure of approval status or quality — the FDA lists "deep discounts or prices that seem too good to be true" among its telehealth red flags.[1]
Free online consult · Provider review within 24–48 hours · 100% self-pay
Sources & Evidence
- 1FDA — FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
"However, compounded drugs are not FDA approved. This means the agency does not review compounded drugs for safety, effectiveness or quality before they are marketed."
- 2FDA — FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
"[2/21/2025] FDA has determined the shortage of semaglutide injection products… is resolved. Semaglutide injection products have been in shortage since 2022 due to increased demand."
- 3FDA News Release (April 30, 2026) — FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List
"…finding no clinical need for outsourcing facilities to compound these drugs from bulk substances."
- 4Federal Register (June 26, 2026) — 503B Bulks List notice; comment period extension
"Either electronic or written comments must be submitted by July 30, 2026."
- 5DailyMed — Ozempic (semaglutide) FDA labeling
"Official FDA prescribing information for Ozempic (semaglutide) — Indications and Usage."
Editorial standards. Ladies First content is written to be medically honest and independently sourced. A claim is only published once a primary source has been fetched and confirmed to support it; claims that cannot be independently verified are removed or routed for clinical sign-off. We describe process, not individuals.
Ladies First is a women's telehealth marketing platform and does not provide medical services. All medical care is provided by our medical provider partner, an independent network of US-licensed medical providers; all medical decisions are made by a medical provider licensed in your state. Compounded medications are not FDA-approved; the FDA does not review compounded preparations for safety, effectiveness, or quality before they are marketed. They are prepared by state-licensed compounding pharmacies operating under USP <795> and/or USP <797> standards and are distinct from FDA-approved, brand-name products. These statements have not been evaluated to diagnose, treat, cure, or prevent any disease. Individual results vary and no outcome is promised. Treatment availability varies by state. 100% self-pay. This page is general information, not medical advice. Ozempic® and Wegovy® are trademarks of Novo Nordisk; Mounjaro® and Zepbound® are trademarks of Eli Lilly. Last reviewed July 2026; regulatory status is evolving and this page is re-scanned on a 30-day cycle.